Lower urinary tract symptoms and its potential relation with late-onset hypogonadism

References

• Rohrmann S, Smit E, Giovannucci E, Platz E A. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2004; 159: 390–397
   PubMed Web of Science ®Google Scholar
• Kasturi S, Russell S, McVary K T. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006; 7: 288–292
   PubMedGoogle Scholar
• Rosen R C. Assessment of sexual dysfunction in patients with benign prostatic hyperplasia. BJU Int 2006; 97: 29–33
   PubMedGoogle Scholar
• McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97: 23–28
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Hoesl C E, Traish A M, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS–implications for clinical practice. Andrologia 2006; 38: 1–12
   PubMed Web of Science ®Google Scholar
• Kaplan S A, Meehan A G, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men?. J Urol 2006; 176: 1524–1527
   PubMed Web of Science ®Google Scholar
• Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239–250
   PubMed Web of Science ®Google Scholar
• Isidori A M, Giannetta E, Greco E A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280–293
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005; 96: 67M–72M
   PubMedGoogle Scholar
• Schatzl G, Brossner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000; 55: 397–402
   PubMed Web of Science ®Google Scholar
• Litman H J, Bhasin S, O'Leary M P, Link C L, McKinlay J B. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health Survey. BJU Int 2007; 100: 321–326
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Nelson W G, Rifai N, Kanarek N, Basaria S, Tsilidis K, Smit E, Giovannucci E, Platz E. Serum sex steroid hormones and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007; 69: 708–713
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335–4343
   PubMed Web of Science ®Google Scholar
• Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat Clin Pract Urol 2007; 4: 161–166
   PubMedGoogle Scholar
• Rosenzweig B A, Bolina P S, Birch L, Moran C, Marcovici I, Prins G S. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 1995; 14: 87–96
   PubMed Web of Science ®Google Scholar
• Salmi S, Santti R, Gustafsson J A, Makela S. Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat. J Urol 2001; 166: 674–677
   PubMedGoogle Scholar
• Keast J R. Plasticity of pelvic autonomic ganglia and urogenital innervation. Int Rev Cytol 2006; 248: 141–208
   PubMedGoogle Scholar
• Keast J R. Effects of testosterone on pelvic autonomic pathways: progress and pitfalls. J Auton Nerv Syst 2000; 79: 67–73
   PubMedGoogle Scholar
• Keast J R, Saunders R J. Testosterone has potent, selective effects on the morphology of pelvic autonomic neurons which control the bladder, lower bowel and internal reproductive organs of the male rat. Neuroscience 1998; 85: 543–556
   PubMedGoogle Scholar
• Keast J R. The autonomic nerve supply of male sex organs - an important target of circulating androgens. Behav Brain Res 1999; 105: 81–92
   PubMed Web of Science ®Google Scholar
• Purves-Tyson T D, Arshi M S, Handelsman D J, Cheng Y, Keast J R. Androgen and estrogen receptor-mediated mechanisms of testosterone action in male rat pelvic autonomic ganglia. Neuroscience 2007; 148: 92–104
   PubMedGoogle Scholar
• Anderson G F, Navarro S P. The response of autonomic receptors to castration and testosterone in the urinary bladder of the rabbit. J Urol 1988; 140: 885–889
   PubMed Web of Science ®Google Scholar
• Takyu S. Effects of testosterone on the autonomic receptor-mediated function in lower urinary tract from male rabbits. Nippon Hinyokika Gakkai Zasshi 1993; 84: 330–338
   PubMedGoogle Scholar
• Holmquist F, Persson K, Bodker A, Anderson K E. Some pre- and post-junctional effects of castration in rabbit isolated corpus cavernosum and urethra. J Urol 1994; 152: 1011–1016
   PubMed Web of Science ®Google Scholar
• Juan Y S, Onal B, Broadaway S, Cosgrove J, Leggett R E, Whitbeck C, De E, Sokol R, Levin R M. Effect of castration on male rabbit lower urinary tract tissue enzymes. Mol Cell Biochem 2007; 301: 227–233
   PubMed Web of Science ®Google Scholar
• Nakazawa R, Tanaka M, Takahashi T, Kobayashi S, Iwamoto T. Effects of castration and testosterone administration on angiotensin II receptor mRNA expression and apoptosis-related proteins in rat urinary bladder. Endocr J 2007; 54: 211–219
   PubMed Web of Science ®Google Scholar
• Peters S L, Schmidt M, Michel M C. Rho kinase: a target for treating urinary bladder dysfunction?. Trends Pharmacol Sci 2006; 27: 492–497
   PubMed Web of Science ®Google Scholar
• Muto S, Yasuda M, Kamiyama Y, Ide H, Horie S. Testosterone decreased urinary-frequency in nNOS-deficient mice. Int J Androl 2007; 31: 67–70
   PubMedGoogle Scholar
• Ehren I, Adolfsson J, Wiklund N P. Nitric oxide synthase activity in the human urogenital tract. Urol Res 1994; 22: 287–290
   PubMedGoogle Scholar
• Smet P J, Jonavicius J, Marshall V R, de Vente J. Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 1996; 71: 337–348
   PubMed Web of Science ®Google Scholar
• Qiu Y, Kraft P, Craig E C, Liu X, Haynes-Johnson D. Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 2001; 29: 388–392
   PubMedGoogle Scholar
• Werkstrom V, Svensson A, Andersson K E, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 2006; 98: 414–423
   PubMed Web of Science ®Google Scholar
• Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Vannelli G B, Carini M, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinol 2007; 148: 1019–1029
   PubMed Web of Science ®Google Scholar
• Chamness S L, Ricker D D, Crone J K, Dembeck C L, Maguire M P, Burnett A L, Chang T S. The effect of androgen on nitric oxide synthase in the male eproductive tract of the rat. Fertil Steril 1995; 63: 1101–1107
   PubMed Web of Science ®Google Scholar
• Truss M C, Stief C G, Uckert S, Becker A J, Wefer J, Schultheiss D, Jonas U. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001; 19: 344–350
   PubMed Web of Science ®Google Scholar
• Sairam K, Kulinskaya E, McNicholas T A, Boustead G B, Hanbury D C. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836–839
   PubMed Web of Science ®Google Scholar
• Montorsi F, Corbin J, Phillips S. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med 2004; 1: 322–336
   PubMed Web of Science ®Google Scholar
• Uckert S, Hedlund P, Andersson K E, Truss M C, Jonas U, Stief C G. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol 2006; 50: 1194–1207
   PubMed Web of Science ®Google Scholar
• Mulhall J P, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662–667
   PubMed Web of Science ®Google Scholar
• McVary K T, Roehrborn C G, Kaminetsky J C, Auerbach S M, Wachs B, Young J M, Esler A, Sides G D, Denes B S. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–1407
   PubMed Web of Science ®Google Scholar
• McVary K T, Monnig W, Camps J L, Young J M, Tseng L J, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–1077
   PubMed Web of Science ®Google Scholar
• Shen Z J, Zhou X L, Lu Y L, Chen Z D. Effect of androgen deprivation on penile ultrastructure. Asian J Androl 2003; 5: 33–36
   PubMed Web of Science ®Google Scholar
• Traish A M, Park K, Dhir V, Kim N N, Moreland R B, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999; 140: 1861–1868
   PubMed Web of Science ®Google Scholar
• Singh R, Artaza J N, Taylor W E, Gonzalez-Cadavid N F, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081–5088
   PubMed Web of Science ®Google Scholar
• Traish A M, Toselli P, Jeong S J, Kim N N. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005; 26: 242–248
   PubMed Web of Science ®Google Scholar
• Traish A M, Munarriz R, O'Connell L, Choi S, Kim S W, Kim N N, Huang Y H, Goldstein I. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003; 24: 381–387
   PubMed Web of Science ®Google Scholar
• Schultheiss D, Badalyan R, Pilatz A, Gabouev A I, Schlote N, Wefer J, von Wasielewski R, Mertsching H, Sohn M, Stief C G, et al. Androgen and estrogen receptors in the human corpus cavernosum penis: immunohistochemical and cell culture results. World J Urol 2003; 21: 320–324
   PubMedGoogle Scholar
• Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli G B, Aversa A, Natali A, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145: 2253–2263
   PubMed Web of Science ®Google Scholar
• Greco E A, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. Eur Urol 2006; 50: 940–947
   PubMed Web of Science ®Google Scholar
• Gooren L J, Saad F. Recent insights into androgen action on the anatomical and physiological substrate of penile erection. Asian J Androl 2006; 8: 3–9
   PubMed Web of Science ®Google Scholar
• McMahon C N, Smith C J, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006; 332: 589–592
   PubMed Web of Science ®Google Scholar
• Yassin A A, Saad F, Traish A. Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. J Sex Med 2006; 3: 727–735
   PubMed Web of Science ®Google Scholar